Amphivena raises $62M Series C round to develop bispecific antibody in solid tumors
The company presented data from a Phase I study in acute myeloid leukemia at the European Hematology Association's annual meeting during the summer.
The company presented data from a Phase I study in acute myeloid leukemia at the European Hematology Association's annual meeting during the summer.
The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
The California-based drugmaker plans to use the money to advance its investigational drugs with MOAs based on immune system responses.
The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.